CN108218798A - Apabetalone的制备方法 - Google Patents
Apabetalone的制备方法 Download PDFInfo
- Publication number
- CN108218798A CN108218798A CN201711331634.5A CN201711331634A CN108218798A CN 108218798 A CN108218798 A CN 108218798A CN 201711331634 A CN201711331634 A CN 201711331634A CN 108218798 A CN108218798 A CN 108218798A
- Authority
- CN
- China
- Prior art keywords
- bromo
- dimethylbenzaldehydes
- reaction
- apabetalone
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229950002797 apabetalone Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims abstract description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 6
- 239000000908 ammonium hydroxide Substances 0.000 claims abstract description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims abstract description 6
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims abstract description 6
- 238000010189 synthetic method Methods 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 69
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 239000000543 intermediate Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 239000012044 organic layer Substances 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 12
- 238000004440 column chromatography Methods 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- PEKSAHQVDKQWST-UHFFFAOYSA-N 2-bromo-4,6-dimethoxybenzaldehyde Chemical class COC1=CC(Br)=C(C=O)C(OC)=C1 PEKSAHQVDKQWST-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 claims description 8
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 claims description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000005457 ice water Substances 0.000 claims description 7
- 150000002460 imidazoles Chemical class 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 7
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007832 Na2SO4 Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- UYGBSRJODQHNLQ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzaldehyde Chemical class CC1=CC(C=O)=CC(C)=C1O UYGBSRJODQHNLQ-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 239000011261 inert gas Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052794 bromium Inorganic materials 0.000 abstract description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 238000011084 recovery Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- KRWRFIMBWRVMKE-UHFFFAOYSA-N 1-bromo-3,5-dimethoxybenzene Chemical class COC1=CC(Br)=CC(OC)=C1 KRWRFIMBWRVMKE-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 2
- JSRIGQZZKGUUTK-UHFFFAOYSA-N 2-bromo-4,6-dimethoxybenzoic acid Chemical class COC1=CC(Br)=C(C(O)=O)C(OC)=C1 JSRIGQZZKGUUTK-UHFFFAOYSA-N 0.000 description 2
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical class COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- -1 Dichloromethane Alkane Chemical class 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NIUZVSQOXJIHBL-UHFFFAOYSA-N 1-bromo-2,4-dimethoxybenzene Chemical class COC1=CC=C(Br)C(OC)=C1 NIUZVSQOXJIHBL-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- VRXVUCLJIJWDMH-UHFFFAOYSA-N Cl.C1=CC=CC2=NC(OC)=NC=C21 Chemical compound Cl.C1=CC=CC2=NC(OC)=NC=C21 VRXVUCLJIJWDMH-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
- C07C51/295—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with inorganic bases, e.g. by alkali fusion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及Apabetalone的制备方法,具体公开了Apabetalone的合成方法,其包括如下步骤:1)制备第一中间体2‑溴‑4,6‑二甲氧基苯甲酰胺;2)制备第二中间体4‑{2‑[(叔丁基二甲基硅)氧]乙氧基}‑3,5‑二甲基苯甲醛;3)将第一中间体和第二中间体在溴化亚铜、碳酸铯、L‑脯氨酸以及氨水的条件下密封进行反应,得到Apabetalone。本发明的制备方法简单,产率高。
Description
技术领域
本发明涉及医药领域,具体涉及Apabetalone的制备方法。
背景技术
Apabetalone(RVX-208),化学名:2-[4-(2-羟乙氧基)-3,5-二甲基苯基]-5,7-二甲氧基喹唑啉–4(3H)-酮,由Resverlogix公司开发,主要用来治疗动脉粥样硬化等心血管疾病[1,2],目前正在进行III期临床研究[3],有非常好的上市前景,该药还进入了阿尔茨海默症治疗的II 期临床研究[4]。Apabetalone是一种选择性作用于BD2溴结构域的BETbromodomain抑制剂[5],对该药的深入研究有助于阐明BET bromodomain的BD1和BD2溴结构域在生理学上所起的作用。Apabetalone,作为载脂蛋白(APO)A-I基因表达的激动剂,在体内外增加 (APO)A-I和HDL-C[1]。本申请发明人还发现Apabetalone有HIV潜伏激活作用[6],对HIV 治愈性研究有极大的意义。
目前文献报道的Apabetalone的合成方法[5,7,8,9,10,11],均采用中间体2-氨基-4,6-二甲氧基苯甲酰胺(A-4)进行合成,收率低,如下所示的反应流程。
该路线以3,5-二甲氧基苯胺(A-1)为原料经成盐、环化、水解、成酰胺、最后成喹唑啉酮环并脱保护,反应条件较为苛刻,如使用草酰氯、高温、易燃易爆的双氧水以及强碱氢氧化钠等,总收率仅为4.8%。文献合成2-氨基-4,6-二甲氧基苯甲酰胺(A-4)共3步,总收率22.6%,收率较低。
[参考文献]
[1]Bailey D,et al.A small molecule that increases apolipoprotein A-Iand high-density lipoprote-in cholesterol in vitro and in vivo[J].J Am CollCardiol,2010,55(23):2580-2589.
[2]Nicholls SJ,et al.ApoA-I induction as a potential cardioprotectivestrategy: Rationale for the SUSTAIN and ASSURE studies[J].Cardiovasc DrugsTher,2012,26(2): 181–187.
[3]Nicholls SJ,et al.Selective BET Protein Inhibition withApabetalone and Cardiovascular Eve-nts:A Pooled Analysis of Trials inPatients with Coronary Artery Disease[J].Am J Cardiova-sc Drugs,2017.
[4]McNeill E.RVX-208,a stimulator of apolipoprotein AI geneexpression for the treatment of cardiovascular diseases[J].Curr Opin InvestigDrugs,2010,11(3):357–364.
[5]Picaud S,Wells C,Felletar I,et al.RVX-208,an inhibitor of BETtranscriptional regulators with selectivity for the second bromodomain[J].Proc Natl Acad Sci USA,2013, 110(49):19 754-19759.
[6]LI L,ZHANG XX,REN RX,et al.Application of RVX-208used as HIV-1latent infection re-versal agent:CN,20161567750[P].2016-12-07.
[7]Norman C.W.Wong,et al.Compounds for the prevention and treatmentof cardiovascular diseases:US,20080188467[P].2008-08-07.
[8]Kevin G.McLure,et al.Treatment of diseases by epigeneticregulation:US, 20130281397[P].2013-10-24.
[9]Henrik C.Hansen,et al.Compounds for the prevention and treatmentof cardiovascular dise-ases:WO,2008092231[P].2008-08-07.
[10]Henrik C.Hansen,et al.Methods of preparing quinazolinonederivatives:WO, 2009158404[P].2009-12-30.
[11]Kevin G.McLure,et al.Treatment of diseases by epigeneticregulation:WO, 2013156869[P].2013-10-24.
[12]Rachelle Quach,et al.Total Synthesis of the Resorcyclic AcidLactone Spiroketal Citreovi-ranol[J].J.Org.Chem.2016,81(18):8343-8350.
[13]Tsutomu Yokomatsu,Kenji Suemune,et al.Highly regioselectivesilylation of α,β-dihydr-oxyphosphonates:An application to stereoselectivesynthesis ofα-amino-β-hy droxyphos-phonic acid derivatives[J].Synlett.1995,1995(8):847-849.
发明内容
为解决上述问题,本发明文设计了一种新的制备Apabetalone的方法,以1-溴-3,5-二甲氧基苯(C-1)原料经酰化、氧化、成酰胺3步反应合成关键中间体2-溴-4,6-二甲氧基苯甲酰胺 (C-4),其3步合成总收率为32%。再与另外一个2步合成的中间体4-{2-[(叔丁基二甲基硅) 氧]乙氧基}-3,5-二甲基苯甲醛(B-3)反应制备Apabetalone,收率达到48%,如下所示的反应流程。
本发明一个方面提供了Apabetalone的合成方法,其包括如下步骤:
1)制备第一中间体2-溴-4,6-二甲氧基苯甲酰胺;
2)制备第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛;
3)将第一中间体和第二中间体在溴化亚铜、碳酸铯、L-脯氨酸以及氨水的条件下密封进行反应,得到Apabetalone。
在本发明的技术方案中,第一中间体的制备方法包括以下步骤:
1-1)3,5-二甲氧基溴苯在惰性气体保护下加入POCl3,室温反应后加热至100℃继续反应至完全,将反应液倒入冰水中,过滤得到1 2-溴-4,6-二甲氧基苯甲醛;
1-2)2-溴-4,6-二甲氧基苯甲醛加入NaClO2、NaH2PO4,再加入tBuOH:H2O混合溶液以及2-甲基-2-丁烯,室温反应至完全,以稀酸溶液中止反应,获得2-溴-4,6-二甲氧基苯甲酸;
1-3)以缩合剂催化2-溴-4,6-二甲氧基苯甲酸,并在碱性条件下与NH3进行反应,获得第一中间体。
其中,步骤1-3)中的缩合剂选自EDCI、HOBt、HOAT、DCC,碱性条件是通过加入 NMM、DIEA或吡啶获得。
在本发明的技术方案中,第二中间体的制备方法包括以下步骤:
2-1)4-羟基-3,5-二甲基苯甲醛和2-氯乙醇在无水碳酸钾在有机溶剂中回流反应至完全获得4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、二甲基叔丁基氯硅烷和咪唑在有机溶剂中进行反应,得到第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛。
在本发明的技术方案中,包括如下步骤:
1-1)3,5-二甲氧基溴苯,DMF,氮气保护于冰浴中,缓慢滴加POCl3,室温搅拌0.5h,加热至100℃继续搅拌3.5h,将反应液倒入冰水中,静置,过滤得化合物2-溴-4,6-二甲氧基苯甲醛;
1-2)在2-溴-4,6-二甲氧基苯甲醛中加入NaClO2和NaH2PO4,再加入tBuOH:H2O=5:1的溶液以及2-甲基-2-丁烯,室温搅拌1h,加入2M的盐酸溶液淬灭,用乙酸乙酯萃取,萃取液用饱和NaCl洗涤,无水Na2SO4干燥,浓缩得化合物2-溴-4,6-二甲氧基苯甲酸;
1-3)2-溴-4,6-二甲氧基苯甲酸,EDC,HOBt,NMM在THF中室温反应,再通NH3反应,加入蒸馏水,用DCM萃取,收集有机层,无水Na2SO4干燥,柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得化合物2-溴-4,6-二甲氧基苯甲酰胺;
2-1)将4-羟基-3,5-二甲基苯甲醛、乙醇、无水碳酸钾和2-氯乙醇回流反应24h;反应液冷却至室温,过滤,滤液减压旋干,用乙酸乙酯稀释后,分别用水和饱和食盐水洗,无水硫酸钠干燥;柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得到4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)将4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、DMF、咪唑和二甲基叔丁基氯硅烷,30℃下搅拌,反应完全,24h后往反应液中加入乙酸乙酯和蒸馏水,分液,分离有机层,水层用乙酸乙酯萃取,合并有机层;蒸馏水和饱和食盐水洗有机层,无水硫酸钠干燥;减压浓缩,柱层析,石油醚/乙酸乙酯(v/v,10:1)洗脱,得4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛;
3)取2-溴-4,6-二甲氧基苯甲酰胺,溴化亚铜,碳酸铯,L-脯氨酸于厚壁耐压管中,加入 DMSO,4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛,26%氨水,密封耐压管; 100℃下密封搅拌12h,再敞口搅拌12h。加饱和氯化铵溶液淬灭,再加乙酸乙酯和蒸馏水,分液,水层用乙酸乙酯萃取,有机层用蒸馏水和饱和食盐水洗,无水硫酸钠干燥;二氯甲烷/ 甲醇(v/v,40:1)柱层析洗脱,得Apabetalone。
本发明另一个方面提供了一种制备Apabetalone中间体2-溴-4,6-二甲氧基苯甲酰胺的方法,其包括如下步骤:
1-1)3,5-二甲氧基溴苯在惰性气体保护下加入POCl3,室温反应后加热至100℃继续反应至完全,将反应液倒入冰水中,过滤得到1 2-溴-4,6-二甲氧基苯甲醛;
1-2)2-溴-4,6-二甲氧基苯甲醛加入NaClO2、NaH2PO4,再加入tBuOH:H2O混合溶液以及2-甲基-2-丁烯,室温反应至完全,以稀酸溶液中止反应,获得2-溴-4,6-二甲氧基苯甲酸;
1-3)以缩合剂催化2-溴-4,6-二甲氧基苯甲酸,并在碱性条件下与NH3进行反应,获得第一中间体。
本发明再一个方面提供了一种制备Apabetalone中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛的方法,其包括如下步骤:
2-1)4-羟基-3,5-二甲基苯甲醛和2-氯乙醇在无水碳酸钾在有机溶剂中回流反应至完全获得4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、二甲基叔丁基氯硅烷和咪唑在有机溶剂中进行反应,得到第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛。
具体实施方式
仪器与试剂
Bruker 400M核磁共振仪(德国布鲁克公司);EYELAN-1100型旋转蒸发仪(日本东京理化公司);循环水式真空泵SHZ–D(III)(巩义市予华仪器有限责任公司);ZQ4000液相色谱-质谱用仪(美国WATERS)。
薄层层析(TLC)板采用硅胶GF 254(青岛海洋化工生产)制备薄层层析板;柱层析采用200-300目硅胶(青岛海洋化工厂);1-溴-3,5-二甲氧基苯(萨恩化学技术有限公司);3,5- 二甲基-4-羟基苯甲醛(萨恩化学技术有限公司);2-氯乙醇(上海艾览化工有限公司);三氯氧磷(萨恩化学技术有限公司);其他试剂为本实验室保存的产品以及市售化学纯或分析纯产品。
实施例1 2-溴-4,6-二甲氧基苯甲醛(C-2)的制备
50ml圆底烧瓶中加入3,5-二甲氧基溴苯(1’)(5.0g,23.0mmol),DMF(11ml),氮气保护于冰浴中,缓慢滴加POCl3(6.4ml,20.8mmol),室温搅拌0.5h,加热至100℃继续搅拌3.5h,将反应液倒入60ml冰水中,静置,过滤得化合物C-2 3.73g,收率66%。1H-NMR(400MHz,CDCl3)δ(ppm):10.30(s,1H,CHO),6.77(s,1H,ArH),6.43(s,1H,ArH), 3.89(s,3H,OCH3),3.87(s,3H,OCH3)。
实施例2 2-溴-4,6-二甲氧基苯甲酸(C-3)的制备
100ml圆底烧瓶中加入2-溴-4,6-二甲氧基苯甲醛(C-2)(3.0g,12.2mmol),NaClO2(4.7g,49.0mmol),NaH2PO4(2.2g,18.4mmol),再加入tBuOH:H2O(5:1)溶液48ml, 2-甲基-2-丁烯(7.8ml,73mmol),室温搅拌1h,加入2M的盐酸溶液11ml淬灭,用乙酸乙酯(50ml×3)萃取,萃取液用饱和NaCl洗涤,无水Na2SO4干燥,浓缩得化合物C-3 2.48 g,收率78%。1H-NMR(400MHz,CDCl3)δ(ppm):6.73(d,1H,ArH),6.44(d,1H,ArH), 3.85(s,3H,OCH3),3.82(s,3H,OCH3)。
实施例3 2-溴-4,6-二甲氧基苯甲酰胺(C-4)的制备
在200ml双颈瓶中加入2-溴-4,6-二甲氧基苯甲酸(C-3)(3.00g,11.5mmol), EDC(3.30g,17.25mmol),HOBt(2.30g,17.25mmol),NMM(40μl,0.36mmol),THF 75ml,室温搅拌4h,再通NH3 1h,停止反应,加入30ml蒸馏水,用DCM(30ml×3) 萃取,收集有机层,无水Na2SO4干燥,柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得化合物C-4 1.85g,收率62%。1H-NMR(400MHz,CDCl3)δ(ppm):6.71(d,1H,ArH)6.43(d, 1H,ArH),6.12(s,1H,1/2×CONH2),5.80(s,1H,1/2×CONH2),3.83(s,3H,OCH3), 3.82(s,3H,OCH3)。
实施例4 4-(2-羟基乙氧基)-3,5-二甲基苯甲醛(B-2)的制备
在50ml单口圆底烧瓶中加入1.05g(7mmol)原料B-1 4-羟基-3,5-二甲基苯甲醛,14ml 乙醇,3.87g无水碳酸钾(28mmol)和2.8ml 2-氯乙醇(3.40g,42mmol),回流反应 24h。反应液冷却至室温,过滤,滤液减压旋干,用100ml乙酸乙酯稀释后,分别用水(20 ml)和饱和食盐水(20ml)洗,无水硫酸钠干燥。柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得1.25g化合物B-2,收率94%。1H-NMR(400MHz,CDCl3)δ(ppm):9.84(s,1H,CHO), 7.53(s,2H,ArH),3.94(m,4H,OCH2CH2 OH),2.33(s,6H,2×CH3)。
实施例5 4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛(B-3)的制备
在25ml圆底烧瓶中加入中间体B-2(1.20g,6.20mmol),DMF 4ml,咪唑(1.06g,15.6mmol)和二甲基叔丁基氯硅烷(1.12g,7.5mmol),30℃下搅拌,TLC监测反应, 24h后往反应液中加入30ml乙酸乙酯和20ml蒸馏水,分液,分离有机层,水层用乙酸乙酯萃取(20ml×3),合并有机层。蒸馏水(20ml×2)和饱和食盐水(20ml)洗有机层,无水硫酸钠干燥。减压浓缩,柱层析,石油醚/乙酸乙酯(v/v,10:1)洗脱,得1.87g化合物B-3,收率98%。1H-NMR(400MHz,CDCl3)δ(ppm):9.82(s,1H,CHO),7.50(s,2H, ArH),3.93(t,2H,OCH2 CH2OH),3.87(t,2H,OCH2 CH2 OH),2.31(s,6H,2×CH3), 0.89(s,9H,C(CH3)3),0.08(s,6H,Si(CH3)2)。
实施例6 2-[4-(2-羟乙氧基)-3,5-二甲基苯基]-5,7-二甲氧基喹唑啉-4(3H)-酮(Apabetalone)的制备
取2-溴-4,6-二甲氧基苯甲酰胺(C-4)(388.5mg,1.50mmol),溴化亚铜(21.5mg,0.15 mmol),碳酸铯(977.5mg,3.00mmol),L-脯氨酸(34.5mg,0.30mmol)于厚壁耐压管中,加入DMSO 5ml,中间体B-3(930mg,3.00mmol),1.90ml 26%氨水,密封耐压管。100℃下密封搅拌12h,再敞口搅拌12h。加6ml饱和氯化铵溶液淬灭,再加50ml乙酸乙酯和 50ml蒸馏水,分液,水层用乙酸乙酯(50ml×3)萃取,有机层用蒸馏水(30ml×2)和饱和食盐水(30ml)洗,无水硫酸钠干燥。柱层析,二氯甲烷/甲醇(v/v,40:1)洗脱,得267mg Apabetalone,收率48%。1H-NMR(400MHz,DMSO-d6)δ(ppm):11.81(s,1H,NH),7.89 (s,2H,ArH),6.73(d,1H,ArH),6.51(d,1H,ArH),4.89(t,1H,OH),3.88(s,3H,OCH3), 3.83(d,5H,OCH3,OCH2 CH2OH),3.73(m,2H,OCH2 CH2 OH),2.30(s,6H,2×CH3);13C-NMR(101MHz,DMSO-d6)δ(ppm):164.64,161.38,160.13,158.86,153.55,152.95, 131.17,128.63,127.63,105.07,101.57,97.96,74.41,60.84,56.35,56.02,16.50。 ESI-Mass for C20H22N2O5:m/z(M-H)+370.02。
本申请报道了Apabetalone合成的新方法,以化合物(C-1)为原料,经酰化、氧化、成酰胺经三步反应制备关键中间体2-溴-4,6-二甲氧基苯甲酰胺(C-4),再与(B-3)为原料成喹唑啉酮环合成Apabetalone,总收率为13.8%,而文献方法[5]的总收率只有4.8%。
中间体(C-4)的合成总收率为32%,文献方法[5,7,8,9,10,11]制备其所使用的中间体(A-4)总收率为22.6%;本文还改进了化合物(B-3)的合成方法,收率由文献[5]的69%提高到了92%。本文报道的Apabetalone合成的新方法,采用的化合物(C-4)比文献方法使用的化合物(A-4)制备收率高,反应条件更温和,操作简便。在成喹唑啉酮环制备Apabetalone时,本文方法收率为48%,文献方法[5,7,8,9,10,11]的收率低于40%。
综上所述,本文报道了以2-溴-4,6-二甲氧基苯甲酰胺(C-4)和(B-3)为原料成喹唑啉酮环合成Apabetalone的新方法,此方法反应条件相对温和,操作简便,收率更高。
Claims (7)
1.Apabetalone的合成方法,其包括如下步骤:
1)制备第一中间体2-溴-4,6-二甲氧基苯甲酰胺;
2)制备第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛;
3)将第一中间体和第二中间体在溴化亚铜、碳酸铯、L-脯氨酸以及氨水的条件下密封进行反应,得到Apabetalone。
2.根据权利要求1所述的制备方法,其中,第一中间体的制备方法包括以下步骤:
1-1)3,5-二甲氧基溴苯在惰性气体保护下加入POCl3,室温反应后加热至100℃继续反应至完全,将反应液倒入冰水中,过滤得到1 2-溴-4,6-二甲氧基苯甲醛;
1-2)2-溴-4,6-二甲氧基苯甲醛加入NaClO2、NaH2PO4,再加入tBuOH:H2O混合溶液以及2-甲基-2-丁烯,室温反应至完全,以稀酸溶液中止反应,获得2-溴-4,6-二甲氧基苯甲酸;
1-3)以缩合剂催化2-溴-4,6-二甲氧基苯甲酸,并在碱性条件下与NH3进行反应,获得第一中间体。
3.根据权利要求2所述的制备方法,其中,步骤1-3)中的缩合剂选自EDCI、HOBt、HOAT、DCC,碱性条件是通过加入NMM、DIEA或吡啶获得。
4.根据权利要求1所述的制备方法,其中,第二中间体的制备方法包括以下步骤:
2-1)4-羟基-3,5-二甲基苯甲醛和2-氯乙醇在无水碳酸钾在有机溶剂中回流反应至完全获得4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、二甲基叔丁基氯硅烷和咪唑在有机溶剂中进行反应,得到第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛。
5.根据权利要求1或2所述的合成方法,其中,包括如下步骤:
1-1)3,5-二甲氧基溴苯,DMF,氮气保护于冰浴中,缓慢滴加POCl3,室温搅拌0.5h,加热至100℃继续搅拌3.5h,将反应液倒入冰水中,静置,过滤得化合物2-溴-4,6-二甲氧基苯甲醛;
1-2)在2-溴-4,6-二甲氧基苯甲醛中加入NaClO2和NaH2PO4,再加入tBuOH:H2O=5:1的溶液以及2-甲基-2-丁烯,室温搅拌1h,加入2M的盐酸溶液淬灭,用乙酸乙酯萃取,萃取液用饱和NaCl洗涤,无水Na2SO4干燥,浓缩得化合物2-溴-4,6-二甲氧基苯甲酸;
1-3)2-溴-4,6-二甲氧基苯甲酸,EDC,HOBt,NMM在THF中室温反应,再通NH3反应,加入蒸馏水,用DCM萃取,收集有机层,无水Na2SO4干燥,柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得化合物2-溴-4,6-二甲氧基苯甲酰胺;
2-1)将4-羟基-3,5-二甲基苯甲醛、乙醇、无水碳酸钾和2-氯乙醇回流反应24h;反应液冷却至室温,过滤,滤液减压旋干,用乙酸乙酯稀释后,分别用水和饱和食盐水洗,无水硫酸钠干燥;柱层析,石油醚/乙酸乙酯(v/v,3:1)洗脱,得到4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)将4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、DMF、咪唑和二甲基叔丁基氯硅烷,30℃下搅拌,反应完全,24h后往反应液中加入乙酸乙酯和蒸馏水,分液,分离有机层,水层用乙酸乙酯萃取,合并有机层;蒸馏水和饱和食盐水洗有机层,无水硫酸钠干燥;减压浓缩,柱层析,石油醚/乙酸乙酯(v/v,10:1)洗脱,得4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛;
3)取2-溴-4,6-二甲氧基苯甲酰胺,溴化亚铜,碳酸铯,L-脯氨酸于厚壁耐压管中,加入DMSO,4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛,26%氨水,密封耐压管;100℃下密封搅拌12h,再敞口搅拌12h。加饱和氯化铵溶液淬灭,再加乙酸乙酯和蒸馏水,分液,水层用乙酸乙酯萃取,有机层用蒸馏水和饱和食盐水洗,无水硫酸钠干燥;二氯甲烷/甲醇(v/v,40:1)柱层析洗脱,得Apabetalone。
6.一种制备Apabetalone中间体2-溴-4,6-二甲氧基苯甲酰胺的方法,其包括如下步骤:
1-1)3,5-二甲氧基溴苯在惰性气体保护下加入POCl3,室温反应后加热至100℃继续反应至完全,将反应液倒入冰水中,过滤得到1 2-溴-4,6-二甲氧基苯甲醛;
1-2)2-溴-4,6-二甲氧基苯甲醛加入NaClO2、NaH2PO4,再加入tBuOH:H2O混合溶液以及2-甲基-2-丁烯,室温反应至完全,以稀酸溶液中止反应,获得2- 溴-4,6-二甲氧基苯甲酸;
1-3)以缩合剂催化2-溴-4,6-二甲氧基苯甲酸,并在碱性条件下与NH3进行反应,获得第一中间体。
7.一种制备Apabetalone中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛的方法,其包括如下步骤:
2-1)4-羟基-3,5-二甲基苯甲醛和2-氯乙醇在无水碳酸钾在有机溶剂中回流反应至完全获得4-(2-羟基乙氧基)-3,5-二甲基苯甲醛;
2-2)4-(2-羟基乙氧基)-3,5-二甲基苯甲醛、二甲基叔丁基氯硅烷和咪唑在有机溶剂中进行反应,得到第二中间体4-{2-[(叔丁基二甲基硅)氧]乙氧基}-3,5-二甲基苯甲醛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711331634.5A CN108218798B (zh) | 2017-12-13 | 2017-12-13 | Apabetalone的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711331634.5A CN108218798B (zh) | 2017-12-13 | 2017-12-13 | Apabetalone的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108218798A true CN108218798A (zh) | 2018-06-29 |
CN108218798B CN108218798B (zh) | 2020-04-24 |
Family
ID=62652135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711331634.5A Active CN108218798B (zh) | 2017-12-13 | 2017-12-13 | Apabetalone的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108218798B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111116493A (zh) * | 2019-12-13 | 2020-05-08 | 上海工程技术大学 | 一种制备Apabetalone的方法、中间体及其中间体的制备方法 |
CN115710202A (zh) * | 2021-08-23 | 2023-02-24 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
CN117886683A (zh) * | 2024-03-15 | 2024-04-16 | 山东德澳精细化学品有限公司 | 一种间氯苯丙酮的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059878A2 (en) * | 2002-01-14 | 2003-07-24 | Pharmacia & Upjohn Company | Thieno (3, 2-b) pyridones as antiviral compounds |
WO2013186612A1 (en) * | 2012-04-19 | 2013-12-19 | Rvx Therapeutics Inc. | The use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bet (bromodomain and extra terminal domain) proteins |
-
2017
- 2017-12-13 CN CN201711331634.5A patent/CN108218798B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059878A2 (en) * | 2002-01-14 | 2003-07-24 | Pharmacia & Upjohn Company | Thieno (3, 2-b) pyridones as antiviral compounds |
WO2013186612A1 (en) * | 2012-04-19 | 2013-12-19 | Rvx Therapeutics Inc. | The use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bet (bromodomain and extra terminal domain) proteins |
Non-Patent Citations (4)
Title |
---|
FERENC SOTI ET AL.: "Synthesis of natural dibenzo-α-pyrones,II. Synthesis of alternariol and alternariol 9-methyl ether", 《CHEM. BER.》 * |
MINGFENG SHAO ET AL.: "Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
RACHELLE QUACH ET AL.: "Total Synthesis of the Resorcyclic Acid Lactone Spiroketal Citreoviranol", 《J.ORG.CHEM.》 * |
SHENGHAI GUO ET AL.: "Rapid assembly of quinazolinone scaffold via copper-catalyzed tandem reaction of 2-bromobenzamides with aldehydes and aqueous ammonia: application to the synthesis of the alkaloid tryptanthrin", 《RSC ADV.》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111116493A (zh) * | 2019-12-13 | 2020-05-08 | 上海工程技术大学 | 一种制备Apabetalone的方法、中间体及其中间体的制备方法 |
CN111116493B (zh) * | 2019-12-13 | 2021-07-27 | 上海工程技术大学 | 一种制备Apabetalone的方法、中间体及其中间体的制备方法 |
CN115710202A (zh) * | 2021-08-23 | 2023-02-24 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
CN115710202B (zh) * | 2021-08-23 | 2024-05-03 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
CN117886683A (zh) * | 2024-03-15 | 2024-04-16 | 山东德澳精细化学品有限公司 | 一种间氯苯丙酮的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108218798B (zh) | 2020-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108218798A (zh) | Apabetalone的制备方法 | |
EP3712130A1 (en) | Method for synthesis of roxadustat and intermediate compounds thereof | |
CN107488139B (zh) | 一种含硫3-芳亚甲基异吲哚啉酮衍生物制备方法 | |
JP7368636B2 (ja) | ロキサデュスタット及びその中間体の合成方法とその中間体 | |
CN102307859A (zh) | 合成闭花木苷的方法 | |
CN106946972B (zh) | 一种具有抗肿瘤活性的熊果酸衍生物及其制备方法 | |
CN105646285B (zh) | 一种维兰特罗中间体及其制备方法和应用 | |
CN115093372B (zh) | 一种咪唑衍生物的合成方法 | |
CN109776488A (zh) | 一种邻位醛基的α-酮酰胺类化合物的合成方法 | |
CN107353256A (zh) | 一锅法合成4‑乙酰基‑1,2,3‑三唑化合物的方法 | |
CN112079775B (zh) | 5-三氟甲基异喹啉-8-甲酸的合成方法 | |
CN115028564A (zh) | 一种吡咯衍生物的合成方法 | |
CN106083804A (zh) | 八元环内酯化合物的一种合成方法 | |
CN106977543A (zh) | 改进的索非布韦中间体的制备工艺 | |
CN108299198B (zh) | 一种1,4-二酮化合物的制备方法 | |
CN105017219B (zh) | 一种p53‑MDM2结合抑制剂二羟基异喹啉衍生物的合成方法 | |
Kraus et al. | A synthesis of a thysanone analog | |
CN100564340C (zh) | (2e,4e)-2-甲基-6-氧代-2,4-庚二烯醛的制备方法 | |
CN106631867A (zh) | 一种合成2‑苯甲酰胺‑3‑芳基丙烯酸酯的方法 | |
CN113511966B (zh) | 三氟甲基取代二氢菲类化合物的合成方法 | |
CN111393346B (zh) | N-Boc-Dolaproine及Boc-Dap DCHA的合成方法 | |
CN110563702B (zh) | 近红外荧光化合物与制备方法及其检测亚铁离子的应用 | |
CN107382952A (zh) | 埃格列净的制备方法及其中间体 | |
CN106432003A (zh) | 一种3‑砜基腈类化合物的合成方法 | |
CN110746337B (zh) | 一种1-甲基-2-氰基-3-脂肪族取代氮杂茂化合物的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |